Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat.
The authors previously reported that FK506 effectively suppressed the induction of experimental autoimmune uveoretinitis (EAU) in rats with much lower doses than cyclosporine A. This study was aimed at analyzing the immune status of the FK506-treated and EAU-suppressed rats and examining the hypothesis whether the agent could induce antigen-specific suppressor T (Ts) cells. It was found that spleens from S-antigen-immunized and FK506-treated rats contained a population of Ts cells inhibiting the proliferative responses of S-antigen-sensitized lymphocytes to S-antigen, yet these cells did not affect the proliferative responses of interphotoreceptor retinoid-binding protein (IRBP)-sensitized lymphocytes to IRBP. The helper T (Th) cells did not exhibit such suppressor activities. Furthermore, transfer of Ts cells from S-antigen-immunized and FK506-treated rats to naive syngenic rats induced partial inhibition of EAU induction or delay of EAU onset after immunizing the recipient rats with S-antigen. Lymphocytes from the EAU-suppressed recipients showed low proliferative response to S-antigen and low levels of antibody to S-antigen. These data thus indicate that FK506 treatment after S-antigen immunization induces an activation of Ts cells specific to S-antigen and that the Ts cells might contribute, at least in part, to the uniquely prolonged and intensive immunosuppression by FK506.
Department of Ophthalmology, School of Medicine University of Tokyo, Japan.
H
H
Kawashima
Y
Y
Fujino
M
M
Mochizuki
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology; D019393:Arrestin; D001327:Autoimmune Diseases / Q000276:immunology*; D003208:Concanavalin A / Q000008:administration & dosage; D000939:Epitopes / Q000276:immunology; D005136:Eye Proteins / Q000008:administration & dosage / Q000276:immunology; D007114:Immunization; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D012173:Retinitis / Q000276:immunology*; D012177:Retinol-Binding Proteins / Q000008:administration & dosage; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology; D016559:Tacrolimus; D014605:Uveitis / Q000276:immunology*; D000099214:Retinol-Binding Proteins, Interstitial
D000900:Anti-Bacterial Agents; D000941:Antigens; D019393:Arrestin; D003208:Concanavalin A; D000939:Epitopes; D005136:Eye Proteins; D007166:Immunosuppressive Agents; D012177:Retinol-Binding Proteins; D016559:Tacrolimus; D000099214:Retinol-Binding Proteins, Interstitial